Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DBV TechnologiesDBVT +1.30%34 Price-to-Tangible-Book is 5.02 as of Sep. 02, 2026. GuruFocus rates DBVT with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,133 Biotechnology companies, DBV Technologies ranks worse than 64.43% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
DBV Technologies Price-to-Tangible-Book Related Terms
DBV Technologies Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for DBV Technologies's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBVT vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, DBV Technologies's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
DBV Technologies (DBVT) has a Price-to-Tangible-Book of 5.02 as of Sep. 02, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on DBV Technologies and its competitors. According to the industry distribution chart, DBV Technologies ranks #730 out of 1133 companies in the Biotechnology industry, placing it in the top 64.4%.
Is DBV Technologies' Price-to-Tangible-Book too high?
DBV Technologies' current Price-to-Tangible-Book is 5.02. The Biotechnology industry median Price-to-Tangible-Book is 3.26. DBV Technologies' value of 5.02 is 54% above this industry median. Based on the distribution chart, DBV Technologies ranks #730 out of 1133 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DBV Technologies has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #730 out of 1133 companies for Price-to-Tangible-Book. This places DBV Technologies in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.26. DBV Technologies' value of 5.02 is 54% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.26, based on 1,133 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DBV Technologies's current Price-to-Tangible-Book of 5.02 is 54% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on DBV Technologies and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DBV Technologies's current Price-to-Tangible-Book is 5.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current Price-to-Tangible-Book of 5.02. The current Price-to-Tangible-Book is 5.02 and 54% above the Biotechnology industry median of 3.26. DBV Technologies' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For DBV Technologies (DBVT), the current Price-to-Tangible-Book is 5.02 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
34GF Score
Get the complete analysis for DBVT
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DBVT has been successfully added to your 
